Kazazian Asset Management LLC Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Kazazian Asset Management LLC bought a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 560 shares of the biopharmaceutical company's stock, valued at approximately $399,000.

Several other institutional investors also recently modified their holdings of REGN. GSA Capital Partners LLP acquired a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter worth about $665,000. Empowered Funds LLC grew its position in shares of Regeneron Pharmaceuticals by 7.1% during the 3rd quarter. Empowered Funds LLC now owns 1,652 shares of the biopharmaceutical company's stock worth $1,737,000 after buying an additional 109 shares during the period. Claro Advisors LLC grew its position in shares of Regeneron Pharmaceuticals by 110.6% during the 3rd quarter. Claro Advisors LLC now owns 478 shares of the biopharmaceutical company's stock worth $502,000 after buying an additional 251 shares during the period. Thrivent Financial for Lutherans grew its position in shares of Regeneron Pharmaceuticals by 16.7% during the 3rd quarter. Thrivent Financial for Lutherans now owns 9,120 shares of the biopharmaceutical company's stock worth $9,587,000 after buying an additional 1,306 shares during the period. Finally, AMG National Trust Bank grew its position in shares of Regeneron Pharmaceuticals by 14.6% during the 3rd quarter. AMG National Trust Bank now owns 220 shares of the biopharmaceutical company's stock worth $231,000 after buying an additional 28 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Analyst Upgrades and Downgrades

REGN has been the topic of several recent analyst reports. Sanford C. Bernstein cut their price objective on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating on the stock in a report on Tuesday, January 7th. Bank of America reiterated an "underperform" rating and set a $565.00 price objective on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 10th. Bernstein Bank cut their price objective on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday, February 4th. BMO Capital Markets cut their price objective on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an "overweight" rating on the stock in a report on Tuesday, February 4th. Finally, Wells Fargo & Company cut their price objective on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating on the stock in a report on Friday, January 10th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $973.13.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN traded down $4.14 on Friday, reaching $658.48. The stock had a trading volume of 1,869,108 shares, compared to its average volume of 634,475. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The firm has a fifty day moving average of $689.43 and a two-hundred day moving average of $815.71. Regeneron Pharmaceuticals, Inc. has a 1-year low of $642.00 and a 1-year high of $1,211.20. The company has a market cap of $71.99 billion, a P/E ratio of 17.20, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating analysts' consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same period in the prior year, the firm posted $11.86 EPS. The company's revenue for the quarter was up 10.3% on a year-over-year basis. On average, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.53%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals's dividend payout ratio is 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.